Last weekend, we also got the 3 year- update on CHECKMATE 067
the Ipi vs Nivo vs Ipi+Nivo study- the one that we don't like as underpowered to show a difference between Ipi+Nivo vs Nivo as THAT of course would have been the real question:
After 3 years, patients alive
After 3 years, patients alive
34% with Ipi
52% with Nivo
58% with Ipi +Nivo
52% with Nivo
58% with Ipi +Nivo
Compared to the 2 year OS of (was presented at AACR by J. Larkin in spring 2017):
45% with Ipi
59% with Nivo
64% with Ipi+ Nivo
59% with Nivo
64% with Ipi+ Nivo
So you indeed see the flattening of the curve- remember: infliction point is around 3 years (that's when the curve bends towards the tail, so patients who reach this will in all likelihood STAY alive)
Important to note: patients WITH BRAF, so BRAF pos did BETTER than BRAF wild-type patients, in particular on the Ipi plus Nivo combo (that's especially for the likes of HAS in France!!!) and this is the highest survival rate we've seen in advanced Melanoma. EVER.
3-year rates of overall survival of BRAF pos:
37% Ipi
56% Nivo
BUT this tops it all:
68% Ipi+ Nivo
56% Nivo
BUT this tops it all:
68% Ipi+ Nivo
Report about it
http://www.medscape.com/viewarticle/885516…
http://www.medscape.com/viewarticle/885516…
Full NEJM paper:
Earlier papers about Checkmate 067:
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1504030